身体成分变化对胃癌新辅助化疗疗效的研究进展
Research Progress on the Effect of Body Composition Changes on Neoadjuvant Chemotherapy for Gastric Cancer
DOI: 10.12677/ACM.2021.1111783, PDF,   
作者: 周文星:青海大学,青海 西宁;马玉滨*:青海大学附属医院,青海 西宁
关键词: 胃癌新辅助化疗身体成分影像检查Gastric Cancer Neoadjuvant Chemotherapy Body Composition Imaging Examination
摘要: 当前,在我国,大部分胃癌病人在初次治疗时就已经被确诊为局部进展期或者晚期,尽管目前局部进展期胃癌病人的大部分治疗方式都还是以手术为主,但是新辅助化疗技术已逐渐成为了标准治疗模式的重要组成部分,合理的新辅助化疗技术可以改善局部进展期胃癌病人的预后。由于新辅助化疗本身就具有个体间的不同差异性,也因此造成了其效果的巨大差异,因此合理的效果预期可以改善治疗质量及减少个体经济成分,从而尽可能地减少癌症进一步发展,而高效精确地预估新辅助化疗效果也是目前亟待解决的临床难点。本文就身体不同成分变化与新辅助化疗的疗效关系的最新展望进行综述。
Abstract: At present, in China, most patients with gastric cancer have been diagnosed as locally advanced or advanced at the time of initial treatment. Although most of the treatment methods of locally advanced gastric cancer patients are mainly still surgery, neoadjuvant chemotherapy technology has gradually formed an important part of the standard treatment mode. Reasonable neoadjuvant chemotherapy can improve the prognosis of patients with locally advanced gastric cancer. Neoadjuvant chemotherapy itself has different individual differences, which also leads to great differences in its effects. Therefore, reasonable effect expectation can improve the treatment quality and reduce individual economic components, so as to reduce the further development of cancer as much as possible. Efficient and accurate prediction of the effect of neoadjuvant chemotherapy is also a clinical difficulty to be solved. This paper reviews the latest prospect of the relationship between the changes of different body components and the efficacy of neoadjuvant chemotherapy.
文章引用:周文星, 马玉滨. 身体成分变化对胃癌新辅助化疗疗效的研究进展[J]. 临床医学进展, 2021, 11(11): 5299-5303. https://doi.org/10.12677/ACM.2021.1111783

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[3] Sasako, M., Sakuramoto, S., Katai, H., et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy with S-1 versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 29, 4387-4393. [Google Scholar] [CrossRef
[4] Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20. [Google Scholar] [CrossRef
[5] Heinemann, V. and Moosmann, N. (2007) Neoadjuvant and Adjuvant Therapies for Solid Tumours. MMW Fortschritte der Medizin, 149, 27-30. [Google Scholar] [CrossRef
[6] 张晓杰, 赵东兵. 局部进展期胃癌新辅助化疗疗效预测进展[J]. 癌症进展, 2021, 19(8): 761-764.
[7] Tchernof, A. and Després, J.P. (2013) Pathophysiology of Human Visceral Obesity: An Update. Physiological Reviews, 93, 359-404. [Google Scholar] [CrossRef] [PubMed]
[8] Silveira, E.A., Kliemann, N., Noll, M., et al. (2021) Visceral Obesity and Incident Cancer and Cardiovascular Disease: An Integrative Review of the Epidemiological Evidence. Obesity Reviews, 22, e13088. [Google Scholar] [CrossRef] [PubMed]
[9] Qi, J., Hu, H., Yaghjyan, L., et al. (2020) Association of Adipose Tissue Distribution with Type 2 Diabetes in Breast Cancer Patients. Breast Cancer: Basic and Clinical Research, 14. [Google Scholar] [CrossRef] [PubMed]
[10] Carr, J.S., Zafar, S.F., Saba, N., et al. (2013) Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma. Journal of Gastrointestinal Cancer, 44, 143-151. [Google Scholar] [CrossRef] [PubMed]
[11] Miyazaki, R., Hoka, S. and Yamaura, K. (2019) Visceral Fat, But Not Subcutaneous Fat, Is Associated with Lower Core Temperature during Laparoscopic Surgery. PLoS ONE, 14, e0218281. [Google Scholar] [CrossRef] [PubMed]
[12] Feng, W., Huang, M., Zhao, X., et al. (2020) Severe Loss of Visceral Fat and Skeletal Muscle after Chemotherapy Predicts Poor Prognosis in Metastatic Gastric Cancer Patients without Gastrectomy. Journal of Cancer, 11, 3310-3317. [Google Scholar] [CrossRef] [PubMed]
[13] Fujiwara, N., Nakagawa, H., Kudo, Y., et al. (2015) Sarcopenia, Intramuscular Fat Deposition, and Visceral Adiposity Independently Predict the Outcomes of Hepatocellular Carcinoma. Journal of Hepatology, 63, 131-140. [Google Scholar] [CrossRef] [PubMed]
[14] Park, H.S., Kim, H.S., Beom, S.H., et al. (2018) Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat after Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the Classic Trial. Annals of Surgical Oncology, 25, 3222-3230. [Google Scholar] [CrossRef] [PubMed]
[15] Miljkovic, I. and Zmuda, J.M. (2010) Epidemiology of Myosteatosis. Current Opinion in Clinical Nutrition and Metabolic Care, 13, 260-264. [Google Scholar] [CrossRef
[16] 黎介寿. 临床营养支持的发展趋势[J]. 肠外与肠内营养, 2010, 17(1): 1-4.
[17] 江志伟, 黎介寿, 李宁. 恶性肿瘤病人的肠内营养支持[J]. 肠外与肠内营养, 2004(2): 118-121.
[18] Blauwhoff-Buskermolen, S., et al. (2016) Loss of Muscle Mass during Chemotherapy Is Predictive for Poor Survival of Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 34, 1339-1344. [Google Scholar] [CrossRef
[19] Stene, G.B., et al. (2015) Changes in Skeletal Muscle Mass during Palliative Chemotherapy in Patients with Advanced Lung Cancer. Acta Oncologica, 54, 340-348. [Google Scholar] [CrossRef
[20] Windsor, J.A. and Hill, G.L. (1988) Grip Strength: A Measure of the Proportion of Protein Loss in Surgical Patients. British Journal of Surgery, 75, 880-882. [Google Scholar] [CrossRef] [PubMed]
[21] Becker, K., Mueller, J.D., Schulmacher, C., et al. (2003) Histomorphology and Grading of Regression in Gastric Carcinoma Treated with Neoadjuvant Chemotherapy. Cancer, 98, 1521-1530. [Google Scholar] [CrossRef] [PubMed]
[22] Shen, W., Punyanitya, M., Wang, Z., et al. (2004) Total Body Skeletal Muscle and Adipose Tissue Volumes: Estimation from a Single Abdominal Cross-Sectional Image. Journal of Applied Physiology (1985), 97, 2333-2338. [Google Scholar] [CrossRef] [PubMed]
[23] 石志文, 李娟, 曾欣, 谢渭芬. L_3骨骼肌指数在疾病预后评估中的应用[J]. 第二军医大学学报, 2019, 40(4): 420-425.
[24] Su, H., Ruan, J., Chen, T., et al. (2019) CT-Assessed Sarcopenia Is a Predictive Factor for Both Long-Term and Short-Term Outcomes in Gastrointestinal Oncology Patients: A Systematic Review and Meta-Analysis. Cancer Imaging, 19, 82. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, M., Shen, Y., Tan, L., et al. (2019) Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-Analysis. Chest, 156, 101-111. [Google Scholar] [CrossRef] [PubMed]
[26] Aleixo, G., Williams, G.R., Nyrop, K.A., et al. (2019) Muscle Composition and Outcomes in Patients with Breast Cancer: Meta-Analysis and Systematic Review. Breast Cancer Research and Treatment, 177, 569-579. [Google Scholar] [CrossRef] [PubMed]
[27] Li, J., Deng, Y., Zhang, M., et al. (2019) Prognostic Value of Radiologically Determined Sarcopenia Prior to Treatment in Urologic Tumors: A Meta-Analysis. Medicine (Baltimore), 98, e17213. [Google Scholar] [CrossRef
[28] 季锐, 汤光宇, 诸静其. 消化系统恶性肿瘤相关肌少症的影像学研究进展[J]. 国际医学放射学杂志, 2020, 43(4): 457-462.